SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068

Project Information

VSV-EBOPLUS

Grant agreement ID: 116068

DOI 10.3030/116068

Project closed

EC signature date 12 June 2017

Start date 1 April 2016

End date 31 March 2023

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 15 430 660,00

EU contribution € 8 553 750,00

Coordinated by

SCLAVO VACCINES ASSOCIATION
Italy

Deliverables

Demonstrators, pilots, prototypes (1)

Web site development and maintenance

Migration

Documents, reports (6)

Distribution of month 36 samples from phase I/II clinical trials in Switzerland and Gabon

Migration

Distribution of month 24 samples from phase I/II clinical trials in Switzerland and Gabon

Migration

Distribution of month 48 samples from phase I/II clinical trials in Switzerland and Gabon

Migration

Distribution of samples (serum, plasma, Paxgene tubes) to partners involved in immunogenicity / transcriptomic studies

Migration

Distribution of month 60 samples from phase I/II clinical trials in Switzerland and Gabon

Migration

Distribution of serum, plasma and RNA samples in pediatric trial in Lambaréné

Migration

Publications

Peer reviewed articles (10)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study

Author(s): Vianello E., Gonzalez-Dias P, van Veen S, Engele CG, Quinten E, Monath TP, Medaglini D, VSV-EBOVAC and VSV-EBOPLUS Consortia, Santoro F, Huttner A, Dubey S, Eichberg M, Ndungu FM, Kremsner PG, Essone PN, Agnandji ST, Siegrist CA, Nakaya HI, Ottenhoff THM, and Haks MC
Published in: The Lancet Microbe, 2021, ISSN 1473-3099
Publisher: The Lancet Publishing Group
DOI: 10.1016/s2666-5247(21)00235-4

Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability

Author(s): Angela Huttner, Selidji Todagbe Agnandji, Olivier Engler, Jay W. Hooper, Steve Kwilas, Keersten Ricks, Tamara L. Clements, Hulda R. Jonsdottir, Sravya Sowdamini Nakka, Sylvia Rothenberger, Peter Kremsner, Roland Züst, Donata Medaglini, Tom Ottenhoff, Ali M. Harandi, Claire-Anne Siegrist on behalf of the VEBCON, VSV-EBOVAC , VSV-EBOPLUS Consortia
Published in: Clin Microbiol Infect, 2023, ISSN 1469-0691
Publisher: Elsevier
DOI: 10.1016/j.cmi.2023.08.026

Global blood miRNA profiling unravels early miRNA signatures of the immunogenicity of licensed Ebola vaccine rVSVΔG-ZEBOV-GP in humans

Author(s): Eleonora Vianello, Josefine Persson, Björn Andersson, Suzanne van Veen, Thomaz Lüscher Dias, Francesco Santoro, Malin Östensson, Ogonna Obudulu, Christopher Agbajogu, Sara Torkzadeh, Helder Nakaya, Donata Medaglini, Claire-Anne Siegrist, Tom H. M. Ottenhoff MD, and Ali M. Harandi. On behalf of the VEBCON, VSV-EBOVAC, and VSV-EBOPLUS Consortia
Published in: iScience, 2023, ISSN 2589-0042
Publisher: Cell Press
DOI: 10.1016/j.isci.2023.108574

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine

Author(s): Francesco Santoro, Alessia Donato, Simone Lucchesi, Sara Sorgi, Alice Gerlini, Marielle Haks, Tom Ottenhoff, Patricia Gonzalez-Dias, VSV-EBOVAC Consortium, VSV-EBOPLUS Consortium, Helder Nakaya, Angela Huttner, Claire-Anne Siegrist, Donata Medaglini, Gianni Pozzi
Published in: Vaccines, Issue 9/2, 2021, Page(s) 67, ISSN 2076-393X
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines9020067

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study

Author(s): Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, José F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara Lemaître, Stéphane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER,
Published in: The Lancet Infectious Diseases, Issue 18/7, 2018, Page(s) 738-748, ISSN 1473-3099
Publisher: The Lancet Publishing Group
DOI: 10.1016/S1473-3099(18)30165-8

Correlates of vaccine-induced protective immunity against Ebola virus disease

Author(s): Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist
Published in: Seminars in Immunology, 2018, ISSN 1044-5323
Publisher: Academic Press
DOI: 10.1016/j.smim.2018.07.003

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Author(s): Angela Huttner, Claire-Anne Siegrist
Published in: Expert Review of Vaccines, Issue 17/12, 2018, Page(s) 1105-1110, ISSN 1476-0584
Publisher: Future Drugs Ltd.
DOI: 10.1080/14760584.2018.1546582

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination

Author(s): David Pejoski, Casimir de Rham, Paola Martinez-Murillo, Francesco Santoro, Floriane Auderset, Donata Medaglini, Gianni Pozzi, Maria Vono, Paul-Henri Lambert, Angela Huttner, Mariëlle C. Haks, Tom H. M. Ottenhoff, Jean Villard, Claire-Anne Siegrist
Published in: npj Vaccines, Issue 5/1, 2020, ISSN 2059-0105
Publisher: Springer Nature
DOI: 10.1038/s41541-020-0179-4

Safety, immunogenicity and risk–benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions

Author(s): Bache Emmanuel Bache, Martin P Grobusch, Selidji Todagbe Agnandji
Published in: Future Microbiology, Issue 15/2, 2020, Page(s) 85-106, ISSN 1746-0913
Publisher: Future Medicine Ltd.
DOI: 10.2217/fmb-2019-0237

Methods for predicting vaccine immunogenicity and reactogenicity

Author(s): Patrícia Gonzalez-Dias, Eva K. Lee, Sara Sorgi, Diógenes S. de Lima, Alysson H. Urbanski, Eduardo Lv Silveira, Helder I. Nakaya
Published in: Human Vaccines & Immunotherapeutics, Issue 16/2, 2020, Page(s) 269-276, ISSN 2164-5515
Publisher: Landes Bioscience
DOI: 10.1080/21645515.2019.1697110